1.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: ILEX-DFMO341, N01-CN-25434-01, UCLA-9812049, UF-453-1998, WCCC-CO-98803, NCI-G99-1509, NCT00003814
|
|
2.
|
Phase: Phase III Type: Treatment Status: Completed Age: 5 to 45 Sponsor: NCI Protocol IDs: NCOG-6G871, BTRC-8625, MDA-DM-88056, NCI-T86-0226D, T86-0226
|
|
3.
|
Phase: Phase III Type: Treatment Status: Completed Age: over 18 Sponsor: NCI Protocol IDs: BTRC-6G901, NCI-T91-0047O, T91-0047
|
|
4.
|
Phase: Phase III Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: MDA-DM-92035, NCI-T92-0114C, T92-0114
|
|
5.
|
Phase: Phase III Type: Prevention Status: Completed Age: 40 to 80 Sponsor: NCI, Other Protocol IDs: CDR0000429552, 2002-2261, UCIRVINE-UCI-2002-2261, NCT00118365
|
|
6.
|
Phase: Phase III Type: Prevention Status: Closed Age: 21 and over Sponsor: NCI, Other Protocol IDs: CDR0000067928, WCCC-CO-9737, NCI-P00-0155, NCT00005884
|
|
7.
|
Phase: Phase II, Phase I Type: Prevention Status: Closed Age: Over 18 Sponsor: NCI Protocol IDs: WCCC-CO-9221, NCI-P97-0096
|
|
8.
|
Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-8525A, NCI-T85-0043D, T85-0043
|
|
9.
|
Phase: Phase II Type: Prevention, Screening Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: WCCC-CO-9285, NCI-G97-1213
|
|
10.
|
Phase: Phase II Type: Prevention Status: Closed Age: 30-55 with exceptions Sponsor: NCI Protocol IDs: KUMC-HSC-6916-96, NCI-P97-0080
|
|
11.
|
Phase: Phase II Type: Prevention Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: UAB-9509, NCI-P97-0082
|
|
12.
|
Phase: Phase II Type: Prevention Status: Completed Age: Over 18 Sponsor: NCI Protocol IDs: CCUM-9555, NCI-P97-0094, NCT00003076
|
|
13.
|
Phase: Phase II Type: Prevention Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: FCCC-94021, NCI-P97-0095
|
|
14.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: ID92-026, P30CA016672, MDA-ID-92026, NCI-P00-0149, CDR0000067921, NCT00006079
|
|
15.
|
Phase: Phase II Type: Prevention Status: Closed Age: 35 to 70 Sponsor: NCI Protocol IDs: UCIRVINE-97-18, UCIRVINE-U01-CA-81886-01, NCI-P00-0164, NCT00006101
|
|
16.
|
Phase: Phase II Type: Prevention Status: Closed Age: 18 to 65 Sponsor: NCI, Other Protocol IDs: ID00-109, P30CA016672, MDA-ID-00109, NCI-P02-0219, CDR0000069278, N01-CN-95040, NCT00033371
|
|
17.
|
Phase: Phase II Type: Treatment Status: Completed Age: no age specified Sponsor: NCI Protocol IDs: NCI-84-C-179, NCI-T84-0477N, T84-0477
|
|
18.
|
Phase: Phase II Type: Treatment Status: Completed Age: no age specified Sponsor: NCI Protocol IDs: RPMI-PPC-764, NCI-T83-0886D
|
|
19.
|
Phase: Phase II Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: MDA-DM-88130, NCI-T88-0236H, T88-0236
|
|
20.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: MAYO-867202, NCI-T89-0006C, T89-0006
|
|
21.
|
Phase: Phase II Type: Prevention Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-895151, EST-C-0490, MAYO-895151, I89-0001, NCI-P91-0008
|
|
22.
|
Phase: Phase II Type: Prevention Status: Closed Age: 40 to 80 Sponsor: Other Protocol IDs: UCI-DFMO/COLON, NCI-P92-0007
|
|
23.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000353198, UAB-9921, UAB-F990728039, NCT00086736
|
|
24.
|
Phase: Phase II Type: Prevention Status: Completed Age: 21 and over Sponsor: Other Protocol IDs: 2001-414, CO00318, NCT00204789
|
|
25.
|
Phase: Phase II Type: Prevention Status: Completed Age: 40 to 80 Sponsor: NCI, Other Protocol IDs: CDR0000067922, 1997-96, NCI-P00-0150, UCIRVINE-97-05, NCT00005882
|